NSEGeneral Updates1 Jul 2026 · 1 Jul 2026, 05:59 pm
General Updates
Medplus Health Services Limited · MEDPLUS
✦ AI Summary▼ NegativeRegulatory
MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received a two-day suspension order for a drug license for a store in Karnataka, resulting in a potential revenue loss of Rs 0.80 lacs.
Analysis Scores
Earnings Impact2/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk6/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment4/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Attachments (1)
📄pdf
Download →
MEDPLUS_01072026175849_Intimation.pdf
View document text
MedPlus Health Services Limited
July 01, 2026
The Listing Department The Listing Department
BSE Limited N ational Stock Exchange of India Limited
Phiroze Jeejebhoy Towers, Exchange Plaza, 5th Floor
Dalal Street, Fort, Plot No. C/1, G Block,
Mumbai – 400001 Bandra - Kurla Complex
BSE Scrip Code: 543427 Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS
Dear Sir/Madam,
Sub: Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015
We would like to inform you that Optival Health Solutions Private Limited, a subsidiary of the company, has
received one suspension order for a Drug License of a store situated in the state of Karnataka:
Pursuant to SEBI Listing Regulations read along with SEBI Master Circular No. HO/49/14/14(7)2025-CFD
POD2/I/3762/2026 dated January 30, 2026, the details of the matter are as follows:
Name(s) of the Nature and details of Date of receipt of Details of the Impact on
Authority the action(s) taken, direction or order, violation(s)/ financial
initiated or order(s) including any contravention(s) operation or
passed interim or interim committed or other activities
orders, or any other alleged to be of the listed
communication committed entity,
from the authority quantifiable in
monetary terms
to the extent
possible
Assistant Director, Suspension of Drug Order received on Under Rule 65 of Potential
Drugs Control License for two days of 30.06.2026 Drugs and Revenue Loss of
Administration, store situated at Cosmetics Act, Rs 0.80 lacs.
Davanagere Circle, Anjaneya Layout 1940 and Drugs
Karnataka. Davanagere and Cosmetics
,Karnataka. Rules, 1945
The same will be available on the website of the Company at www.medplusindia.com and also on the websites
of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com
respectively. Kindly take the same on records.
For MedPlus Health Services Limited
Gangadi Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097
040-6724 672
Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India
CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com